Muñoz-Hernando Leticia, Muñoz-Gonzalez Jose L, Marqueta-Marques Laura, Alvarez-Conejo Carmen, Tejerizo-García Álvaro, Lopez-Gonzalez Gregorio, Villegas-Muñoz Emilia, Martin-Jimenez Angel, Jiménez-López Jesús S
Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Carlos Haya, Malaga, Spain.
Int J Womens Health. 2015 Jun 11;7:595-603. doi: 10.2147/IJWH.S78829. eCollection 2015.
Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although in most women a combination of both treatments is required. Long-term medical treatment is usually needed in most women. Unfortunately, in most cases, pain symptoms recur between 6 months and 12 months once treatment is stopped. The authors conducted a literature search for English original articles, related to new medical treatments of endometriosis in humans, including articles published in PubMed, Medline, and the Cochrane Library. Keywords included "endometriosis" matched with "medical treatment", "new treatment", "GnRH antagonists", "Aromatase inhibitors", "selective progesterone receptor modulators", "anti-TNF α", and "anti-angiogenic factors". Hormonal treatments currently available are effective in the relief of pain associated to endometriosis. Among new hormonal drugs, association to aromatase inhibitors could be effective in the treatment of women who do not respond to conventional therapies. GnRH antagonists are expected to be as effective as GnRH agonists, but with easier administration (oral). There is a need to find effective treatments that do not block the ovarian function. For this purpose, antiangiogenic factors could be important components of endometriosis therapy in the future. Upcoming researches and controlled clinical trials should focus on these drugs.
子宫内膜异位症是一种炎症性雌激素依赖性疾病,其定义为子宫外部位存在子宫内膜腺体和间质。子宫内膜异位症管理的主要目的是减轻与该疾病相关的疼痛。这可以通过手术或药物治疗来实现,不过在大多数女性中,两种治疗方法通常都需要结合使用。大多数女性通常需要长期药物治疗。不幸的是,在大多数情况下,一旦停止治疗,疼痛症状会在6个月至12个月之间复发。作者对与人类子宫内膜异位症新药物治疗相关的英文原创文章进行了文献检索,包括发表在PubMed、Medline和Cochrane图书馆的文章。关键词包括与“药物治疗”“新治疗方法”“GnRH拮抗剂”“芳香化酶抑制剂”“选择性孕激素受体调节剂”“抗TNFα”和“抗血管生成因子”相匹配的“子宫内膜异位症”。目前可用的激素治疗对缓解与子宫内膜异位症相关的疼痛有效。在新的激素药物中,与芳香化酶抑制剂联合使用可能对常规治疗无反应的女性有效。GnRH拮抗剂预计与GnRH激动剂一样有效,但给药更方便(口服)。需要找到不阻断卵巢功能的有效治疗方法。为此,抗血管生成因子可能是未来子宫内膜异位症治疗的重要组成部分。即将开展的研究和对照临床试验应聚焦于这些药物。